Recent reports have demonstrated improved survival and outcomes for hepatic resection in metastatic colorectal adenocarcinoma. We have performed a retrospective cohort study for hepatic resections for metastatic colorectal adenocarcinoma between 2004 and 2008. During this time period, we have performed 60 hepatic resections for metastatic colorectal cancer in 59 patients; 3 patients were lost to follow-up. 25/59 (42.4%) had synchronous disease and 34/59 (57.6%) had metachronous disease. 46/59 (77.9%) received chemotherapy prior to liver resection, with various regimens. Of the regimens, 38/46 (82.6%) involved FOLFOX or FOLFIRI therapy. 32/59 (54.2%) patients were noted to be node positive at colon resection. Of resected patients, 50/60 (83.3%) received preoperative PET scans; of preoperative PET scans performed, 7/50 (14.0%) patients possessed extra-hepatic disease. The mean number of liver tumors note in preoperative imaging was 2.4 (standard deviation - 2.3), and the greatest dimension of primary hepatic metastasis was noted to be 4.06 cm (standard deviation - 2.0 cm). Hepatic margins were free of tumor in 41/59 (69.5%) of resections. The median follow up is 16.7 months. Median overall survival was not reached during this follow-up period. 2 year overall survival is 80%. Median disease free survival is 25.9 months. 30-day mortality for hepatic resection was 0%. Overall disease free interval was 13.9 months, 9.4 months for no preoperative treatment, and 16.9 months for neoadjuvant chemotherapy. CONCLUSION: Oxalaplatin-based therapy may be delivered safely before liver resection and combined with surgery yields extended survival in a group of patients with high risk liver metastases from colorectal cancer.